Animal Health Asia 2019 | Kisaco Research
Tokyo, Japan | Dates TBC
5-6 November, 2019
Register
The Audience
Highlight Video

Why Attend

Animal Health Innovation Asia is a premier B2B conference showcasing emerging Animal Health and Nutrition companies, from Japan and across Asia-Pacific, that are actively seeking financial investment or strategic partnership conversations with large corporate firms.

Our plenary sessions provide guidance on veterinary market trends and animal health industry dynamics in Japan & APAC, insight on how emerging companies are using new innovations to prevent disease and market analysis on the M&A activity across the animal health and nutrition markets in Asia.

250+
Attendees
24+
Private Meetings Per Person
8+
hours dedicated networking time
14
Emerging companies presenting
2
TRACKS COVERING HEALTH AND NUTRITION

Testimonials

"This is a unique event for our animal health industry. It brings local and international players together, and provides an excellent platform to build business partnerships.”

Tony Zilong Tan, Z-Link Biotech Co. Ltd.

 

“This meeting is a very exciting one – it’s a platform to meet everyone from Chinese animal health and International animal health companies, and to introduce them to one-another. This way you save time and it gives you more chance to keep ahead of the innovations.”

Tingwu Xue, China Animal Husbandry Group (CAHG)

 

“I think this is a great meeting for companies to come together and find out what the common challenges are and how they can work together. I’m really impressed!"

Jishu Shi, U.S.-China Centre for Animal Health

 

"Everybody’s here, you can have many meetings in one spot, learn how to work together, increase your network and search for ideas.”
Joachim Hasenmaier, Boehringer-Ingelheim

Highlights from the Series

       

Innovation Showcase

Our Selection Committee will select twelve Emerging/ Start-up companies from the list of applications to present on-site to the audience of strategic partners from APAC, Japan and around the world. These presentations will showcase the innovation and opportunity that the emerging companies bring to their various markets.

Submissions will be accepted from companies in the following categories: Nutrition and Health for Livestock or Companion Animals. They should be early to mid-stage companies that are actively looking for financial investment or strategic partnerships, and can range from pre-revenue companies all the way up to larger entities that have annual revenues of up to $10 million USD.

Applications open in mid-2019!

Who You Will Meet

Attendees will represent the following key stakeholder groups in the Animal Health market

  • Heads of Business Development, Animal Health, R&D from Multinational Pharmaceutical Companies
  • CEOs, CSOs and Heads of Business Development from Emerging Animal Health Companies
  • CEOs, Heads of Business Development, Product Discovery and Marketing from Incubators/ Accelerators, Contract Research Orgs, Consultants, Lawyers and other Service Providers

…all of the above with an interest in Livestock, Aquaculture and the Companion Animal markets

Attendees expected from the following key stakeholder groups and organizations

Resources

Download Resource

We need some information to know where to send the link and how to address our email to you. Please note, a link to the PDF will also become immediately available once this form is submitted.

To prevent automated spam submissions leave this field empty.

Subject Access Requests: If you would like a copy of the data/information we hold about you, please email [email protected].

User Deletion Request: If you wish to have your information that is held by Kisaco Research deleted, please email [email protected].

For more information on Kisaco Research policy and procedures, please visit our Privacy Policy.

The Agenda

You can download the 2018 agenda here.

Hong Kong 2018 was another brilliant event in the series. Take a look at the agenda here; and please check back in mid-2019 for the latest agenda for our Tokyo event 2019.

Download the 2018 Agenda

We need some information to know where to send the link and how to address our email to you. Please note, a link to the PDF will also become immediately available once this form is submitted.

To prevent automated spam submissions leave this field empty.

Subject Access Requests: If you would like a copy of the data/information we hold about you, please email [email protected].

User Deletion Request: If you wish to have your information that is held by Kisaco Research deleted, please email [email protected].

For more information on Kisaco Research policy and procedures, please visit our Privacy Policy.

2018 Speakers

 

Dr. Cai XuePeng

President
Chinese Veterinary Association (CVMA)

Dr. Cai Xuepeng has been President of Chinese Veterinary Association (CVMA) since February 2017. In his professional career, he held a number of prominent leadership roles in government institutions related to control of animal diseases and animal health, including as former Director of Lanzhou Veterinary Research Institute, Director of the Chinese Center for Animal Disease Control and Prevention (CCDC), Director of China Institute of Veterinary Drug Control (IVDC), and Director of Veterinary Drug Evaluation Committee, the Ministry of Agriculture. Dr.

Dr. Cai XuePeng

President
Chinese Veterinary Association (CVMA)

Dr. Cai Xuepeng has been President of Chinese Veterinary Association (CVMA) since February 2017. In his professional career, he held a number of prominent leadership roles in government institutions related to control of animal diseases and animal health, including as former Director of Lanzhou Veterinary Research Institute, Director of the Chinese Center for Animal Disease Control and Prevention (CCDC), Director of China Institute of Veterinary Drug Control (IVDC), and Director of Veterinary Drug Evaluation Committee, the Ministry of Agriculture. Dr. Cai received his degree in Veterinary Medicine from Heilongjiang College of Animal Husbandry and Veterinary Medicine, his Master’s Degree in Parasitology from Chinese Academy of Agricultural Sciences, and his PhD in Veterinary Medicine from Nanjing Agricultural University.

才学鹏
中国兽药协会会长
才学鹏先生自2017年2月起担任中国兽药协会会长一职。在他的职业生涯中,他先后担任过与动物疾病防治有关的政府和科研机构要职,包括兰州兽医研究所所长、中国动物疫病预防控制中心主任、中国兽医药品监察所所长和农业部兽药评审中心主任。他本科毕业于黑龙江畜牧兽医学校兽医学专业;在中国农业科学院研究生院兽医寄生虫学与寄生虫病学专业取得硕士学位;在南京农业大学获得了兽医博士学位。

 

Dr. Isabelle Dieuzy-Labaye

Senior Advisor, Public-Private Partnerships
World Organization for Animal Health (OIE)

Dr. Isabelle Dieuzy-Labaye is Senior Advisor, Public-Private Partnerships, at the World Organisation for Animal Health (OIE), an intergovernmental organisation with 182 Member Countries, headquartered in Paris.

Dr. Isabelle Dieuzy-Labaye

Senior Advisor, Public-Private Partnerships
World Organization for Animal Health (OIE)

Dr. Isabelle Dieuzy-Labaye is Senior Advisor, Public-Private Partnerships, at the World Organisation for Animal Health (OIE), an intergovernmental organisation with 182 Member Countries, headquartered in Paris.

She has over 20 years of experience in the animal health market and in the life sciences and innovation sectors, working in the US and now in Europe. Prior to her appointment at the OIE in November 2016, Isabelle was the Director, Strategic Alliances, for Europe, Africa and the Middle East at Zoetis, the leading animal health company worldwide. In this role, she started and led multiple open innovation initiatives through collaborations with various partners at the public-private interface, including large academic research entities, government institutions, startup companies, foundations and charities, driving scientific and developmental projects towards outcome and impact.

Isabelle is a board member at Ecole Nationale Vétérinaire d’Alfort and at the Moredun Research Institute in Scotland. She is also a member of the Strategic Committee of Agreenium, the French consortium of agronomical education and research institutes, and of the Technical and Scientific Committee of GALVmed, a UK-based NGO which makes livestock vaccines, medicines and diagnostics accessible and affordable to developing countries. She recently joined the Scientific Council of the Animal Health Department of INRA.

Isabelle holds a DVM from Ecole Nationale Vétérinaire d’Alfort and obtained her MBA at INSEAD.

 

Clinton Lewis

Clinton Lewis Executive Vice President, President, International Operations
ZOETIS

Clint Lewis is executive vice president and president of International Operations at Zoetis. In this role, he oversees the management of the livestock and companion animal business markets outside the United States.
Mr. Lewis previously served as president, U.S. Operations at Zoetis and in the Pfizer Animal Health organization. He joined Pfizer Animal Health in 2007.

Clinton Lewis

Clinton Lewis Executive Vice President, President, International Operations
ZOETIS

Clint Lewis is executive vice president and president of International Operations at Zoetis. In this role, he oversees the management of the livestock and companion animal business markets outside the United States.
Mr. Lewis previously served as president, U.S. Operations at Zoetis and in the Pfizer Animal Health organization. He joined Pfizer Animal Health in 2007.

Mr. Lewis joined Pfizer in 1988 as a sales representative in Long Island, N.Y., and has held positions of increasing responsibility in several areas across various commercial operations dedicated to human health prior to joining animal health, including vice president and general manager of Pfizer’s U.S. Anti-Infectives/HIV business unit.

In 2011, Mr. Lewis was elected chairman of the Animal Health Institute (AHI) for the 2011-12 term. A member of AHI since 2007, Mr. Lewis previously served as AHI vice chair for the 2009-2010 term. AHI is the trade association for the animal health industry in the U.S. advocating on various issues important to the industry, including efficient and effective regulatory and approval processes by the U.S. Department of Agriculture (USDA), the Food and Drug Administration (FDA), and the Environmental Protection Agency (EPA).

Mr. Lewis holds a bachelor’s degree in biology from Fairfield University and a Master of Business Administration in marketing from Fairleigh Dickinson University.

 

Sébastien Huron

Chairman of the Executive Board
Virbac Santé Animale

Sébastien Huron, 46, DVM, started his career in 1994 in Brazil in the Hoechst-Roussel group where he rapidly rose to become the Marketing director of the animal health division. After Intervet acquired this division (Akzo Nobel group), which was then integrated into the Merck Group, Sébastien Huron pursued his career in 2000 in the United States as Market Development director, and then as director of the Pet division.

Sébastien Huron

Chairman of the Executive Board
Virbac Santé Animale

Sébastien Huron, 46, DVM, started his career in 1994 in Brazil in the Hoechst-Roussel group where he rapidly rose to become the Marketing director of the animal health division. After Intervet acquired this division (Akzo Nobel group), which was then integrated into the Merck Group, Sébastien Huron pursued his career in 2000 in the United States as Market Development director, and then as director of the Pet division. After rejoining the Virbac group in 2006 as the general manager of the Spanish subsidiary, he then became the director of the European region in 2008, and then head of Global Business Operations in 2013. He has been part of the Virbac executive board since December 2012.

 

Ruiai Chen

President
Wen’s Dahuanong

Dr. Ruiai Chen received her Ph.D. in Microbiology from the China Agricultural University. Currently she is a professor and Ph.D. advisor at the College of Veterinary Medicines, South China Agricultural University.

Ruiai Chen

President
Wen’s Dahuanong

Dr. Ruiai Chen received her Ph.D. in Microbiology from the China Agricultural University. Currently she is a professor and Ph.D. advisor at the College of Veterinary Medicines, South China Agricultural University.

Dr. Chen is President of Guangdong Wens Dahuanong Biotechnology Co., Ltd. (DHN), and Vice-Chairman of the China Veterinary Drug Association (CVDA). She is one of the most influential leaders in the Chinese animal health arena and, as a result, she is entitled to special allowances provided by the Chinese State Council, an honor for outstanding scientists in China. Dr. Chen is a well-known expert in the prevention and control of animal diseases, and vaccine research.

She possesses 41 patents and 22 new veterinary drug certificates. Dr. Chen has received 14 technical awards at the provincial and national levels, such as first prize for the Guangdong Provincial Science and Technology Award and the China Outstanding Patent. Her achievements include the development and industrialization of avian influenza vaccines, PRRS vaccines and coccidiosis vaccines. These vaccines are now making great contributions to disease control in China, Southeast Asia (e.g., Indonesia), and Middle East countries. Dr. Chen is also director of the Enterprise Key Laboratory of MOA for Animal Disease Prevention and Control, Biotechnology and Biological Product R&D. She has contributed greatly to commercialization of technology for animal vaccine and pharmaceutical products.

 

Dr. Jihong Kim

Chairman
Green Cross Veterinary Products Co., Ltd.

Dr. Jihong Kim is the chairman of Green Cross Veterinary Products Co., Ltd.. a leading animal health company in South Korea established since 1973. In his role, he is leading the international partnership and globalization initiatives.

Dr. Jihong Kim

Chairman
Green Cross Veterinary Products Co., Ltd.

Dr. Jihong Kim is the chairman of Green Cross Veterinary Products Co., Ltd.. a leading animal health company in South Korea established since 1973. In his role, he is leading the international partnership and globalization initiatives.

Dr. Kim holds MBA from Harvard Business School and PhD from University of California, Berkeley. He was a professor and an associate dean of Korea Development Institute School of Public Policy and Management. He received Official Commendation from Vice Prime Minister, Ministry of Economy and was an Advisory Board Member of Ministry of Finance and Economy, South Korea.

 

Scott Holmstrom

Senior Director, Global Product Development
Elanco

Currently, Dr. Holmstrom leads Elanco’s global food animal product development efforts for pharmaceutical and vaccine products for swine, poultry, beef, dairy, and aqua. In this role, he provides the strategic direction for the global development of products through external and internal coordination, governance, and resourcing.

Scott D. Holmstrom, Ph.D., received his doctorate in analytical chemistry from Miami University in 2000 and joined Elanco Animal Health the same year.

Scott Holmstrom

Senior Director, Global Product Development
Elanco

Currently, Dr. Holmstrom leads Elanco’s global food animal product development efforts for pharmaceutical and vaccine products for swine, poultry, beef, dairy, and aqua. In this role, he provides the strategic direction for the global development of products through external and internal coordination, governance, and resourcing.

Scott D. Holmstrom, Ph.D., received his doctorate in analytical chemistry from Miami University in 2000 and joined Elanco Animal Health the same year.

As a research scientist from 2000 through 2006, Dr. Holmstrom has provided chemistry and drug disposition expertise and significant contributions toward the development and commercialization of drug products for Elanco, including global approvals for Comfortis and Trifexis. His work has influenced numerous companion animal and food animal programs targeting ectoparasites, endoparasites, coccidiosis, ketosis, and feed efficiency. In these assignments, Dr. Holmstrom has developed and validated analytical and bioanalytical methods, and led technical teams to elucidate the metabolism, pharmacokinetics, and pharmacodynamics of existing products and new compounds.

From 2006 - 2012, Dr. Holmstrom led cross-functional product development teams to obtain global registration of new chemical entities for companion animals, targeting parasiticides. Additionally, from 2011 – 2013, he served to integrate the Jannsen Animal Health research and development efforts with those of Elanco.

From 2013-2016, Dr. Holmstrom led global regulatory affairs for Elanco. In this role, he was responsible for shaping the regulatory landscape to enable outcomes for Elanco, their customers, as well as ensure that Elanco deliverables are completed in accordance with appropriate regulations and commitments to global regulatory authorities. This position provides direction for activities according to the company objectives and plays a key role in the development of short term and long-term company strategy.

In 2016, Scott led Elanco’s efforts for development and execution on late stage external innovation strategies.  In this role, he developed specific strategies and execution plans to collaborate with external companies to commercialize products will support near and mid-term growth objectives for Elanco.

 

Alex T. Zhang

Founding Partner
Hosen Capital

More than 20 years' professional experiences in equity investment, management consulting and founder of three successful technology companies

Alex T. Zhang

Founding Partner
Hosen Capital

More than 20 years' professional experiences in equity investment, management consulting and founder of three successful technology companies

 

Dr. Hu Hongbin

President
EFEV Group

Occupation:

The president of Beijing E-feed & E-vet (EFEV) Co.Ltd

The Director of Veterinary Drugs Distribution and Service working committee, CVDA

The Compere of International Animal Health Forum, CVDA (China Veterinary Drugs Association)

The Chairman of Beijing Veterinary Drugs Association

The Vice Chairman of China Feed Economy Committee

 

Education:

1985-1990 Veterinary College, China Agriculture University (Bachelor of Veterinary Science)

Dr. Hu Hongbin

President
EFEV Group

Occupation:

The president of Beijing E-feed & E-vet (EFEV) Co.Ltd

The Director of Veterinary Drugs Distribution and Service working committee, CVDA

The Compere of International Animal Health Forum, CVDA (China Veterinary Drugs Association)

The Chairman of Beijing Veterinary Drugs Association

The Vice Chairman of China Feed Economy Committee

 

Education:

1985-1990 Veterinary College, China Agriculture University (Bachelor of Veterinary Science)

2003-2006 Animal Medical College, China Agriculture University (Master of Veterinary Science)

 

Occupational History:

1990-1991 Veterinarian, Beijing Dongsheng Agriculture & Animal Husbandry Co.Ltd

1992-1994 Sales Consultant/Mainland of China, Veterinary Medicine Division of MSD (Hong Kong) Co.Ltd

1995-1999 Marketing & Sales Director/Great China Region, Animal Health Division of Hoechst GmbH

2000-2001 Sales Manager/China, Intervet Animal health Co.Ltd

2002-     President of Beijing E-feed & E-vet (EFEV) Co.Ltd

 

Dr Xu Bing

President
Golden Vet

Education:

PHD, veterinarian, China Agricultural University

 

Main Working experience:

2010-present,  Chairman, Beijing GoldenVet Biotech Co., Ltd.

2002-2010, Chief Representative (China), Virbac

1999-2002, Marketing manager (China), Schering-Plough Animal health.

1997-1999, Regional Sales Manager, Roche (China) Investment Co., Ltd.

1995-1997, Sales Rep, Conti (Beijing) Feed Additives Ltd.

 

Dr Xu Bing

President
Golden Vet

Education:

PHD, veterinarian, China Agricultural University

 

Main Working experience:

2010-present,  Chairman, Beijing GoldenVet Biotech Co., Ltd.

2002-2010, Chief Representative (China), Virbac

1999-2002, Marketing manager (China), Schering-Plough Animal health.

1997-1999, Regional Sales Manager, Roche (China) Investment Co., Ltd.

1995-1997, Sales Rep, Conti (Beijing) Feed Additives Ltd.

 

 

Emma Davies

Partner
Clifford Chance

Emma Davies advises international clients on M&A and joint ventures in the Asia region, with particular focus on mainland China.

Emma heads up the firm's Corporate practice in mainland China and its Healthcare and Life Sciences Group in Asia.

Emma founded the China competition practice of Clifford Chance and continues to advise clients on the firm's more contentious merger clearances in the market.

Emma Davies

Partner
Clifford Chance

Emma Davies advises international clients on M&A and joint ventures in the Asia region, with particular focus on mainland China.

Emma heads up the firm's Corporate practice in mainland China and its Healthcare and Life Sciences Group in Asia.

Emma founded the China competition practice of Clifford Chance and continues to advise clients on the firm's more contentious merger clearances in the market.

 

Tony Zi Long Tan

Founder and Managing Partner
Z-LINK BIOTECH

Dr. Tan has over 30 years experience in the field of animal health across a range of animal species. He has had management roles in R&D, regulatory affairs, manufacturing, marketing, sales, and business development. Dr. Tan has extensive international business experience and has worked in the USA, Europe and Asia (particularly in China). Dr. Tan is the founder and Managing Partner of Z-Link Biotech Co. Ltd., a service and support company that helps animal health organizations to achieve their growth and stakeholder value in the emerging market.

Tony Zi Long Tan

Founder and Managing Partner
Z-LINK BIOTECH

Dr. Tan has over 30 years experience in the field of animal health across a range of animal species. He has had management roles in R&D, regulatory affairs, manufacturing, marketing, sales, and business development. Dr. Tan has extensive international business experience and has worked in the USA, Europe and Asia (particularly in China). Dr. Tan is the founder and Managing Partner of Z-Link Biotech Co. Ltd., a service and support company that helps animal health organizations to achieve their growth and stakeholder value in the emerging market.

Dr. Tan received his veterinary degree from Foshan Veterinary College in China, his Master’s Degree in Animal Science from Alcorn State University, and his Ph.D. in Microbiology from Kansas State University. During his earlier research career, Dr. Tan helped develop several vaccines for cattle, dogs, and poultry. He has published over 50 scientific publications and research reports.

Dr. Tan served Intervet-Schering Plough (now Merck/MSD Animal Health) for over 15 years in different positions, including R&D Group Leader, Project Manager Vaccine Manufacturing, Technical Marketing Manager Aquatic Animals, and Business Unit Director Companion Animals China.

From 2009 to March 2016, Dr. Tan was Group Director of Business Development and Global Alliances for the Asia-Pacific Region of Zoetis (formerly Pfizer Animal Health). He successfully completed several large M&A transactions (total transaction value in excess of US$100 million) and a number of technology licensing deals. These include the first antitrust divesture project in China, the company’s first joint venture project for vaccine manufacturing, and divesture of a pharmaceutical manufacturing plant in Taiwan.

Dr. Tan is an Advisor to the China Global Investment & Trading Alliance (CGITA), an organization that promotes international business between China and other countries.

谭博士在动物保健领域从业超过30年,涉及各种动物品种和岗位部门,包括研发、产品注册、生产、市场、销售以及业务拓展。谭博士拥有丰富的国际工作经验,曾在美国、欧洲和亚洲(特别是中国)国家工作。谭博士是易联生物科技有限公司的创始人。易联生物科技是一家咨询公司帮助动保公司在新兴市场服的发展。

谭博士毕业于佛山兽医专科学校、从阿尔肯州立大学取得了动物科学的硕士学位、从堪萨斯州立大学取得了微生物学的博士学位。在他的研究生涯中,为牛、狗以及家禽类开发了数种疫苗,并且发表了超过50篇科学论文和研究报告。

谭博士在英特威/默沙东动物保健公司工作了超过15年,期间担任了不同职位,包括研发部主管、疫苗制造项目经理、水生动物的技术市场经理以及中国伴侣动物的事业部总监。

从2009年到2016年,谭博士在硕腾(原名辉瑞)担任业务拓展部门和国际联盟亚太地区高级总监。他成功地完成了数项重大企业并购交易(总交易额超过一亿美元)和若干技术转让项目。其中包括中国第一个反垄断剥离项目,辉瑞在中国的第一个合资企业和出售台湾的一家医药制造工厂。

此外,谭博士还是中国际投资和贸易联盟(CGITA)的顾问。CGITA是一个致力于促进中国和其他国家之间国际商务的组织。

 

Dr. Zhao Yarong

Tianjin Ringpu

Professor, Yarong ZHAO received Ph.D. in Veterinary Parasitology from China Agricultural University in 1993. With his cutting-edge researches in cryptosporidiosis, he received the First Grade Science & Technology Award from the Chinese Ministry of Agriculture in 1993.

From 1993 to 1998, he worked as National Technical Manager in Bayer Animal Health China. Later then in Fort Dodge Animal Health and Schering-Plough China as Regulatory and Technical Manager.

Dr. Zhao Yarong

Tianjin Ringpu

Professor, Yarong ZHAO received Ph.D. in Veterinary Parasitology from China Agricultural University in 1993. With his cutting-edge researches in cryptosporidiosis, he received the First Grade Science & Technology Award from the Chinese Ministry of Agriculture in 1993.

From 1993 to 1998, he worked as National Technical Manager in Bayer Animal Health China. Later then in Fort Dodge Animal Health and Schering-Plough China as Regulatory and Technical Manager.

In 2003, he was appointed as General Manager of the Animal Medicine Research Center of the Dabeinong (DBN) Group, an innovative R&D center which focusing on animal infection disease diagnosis, animal biologic development and technology transfer. He has published over 50 scientific papers. Under his leadership, the Center has obtained Six National New Veterinary Drug Certificates and complete a number of technology transfer to other animal health companies with a total transaction value of approximately 350 million(RMB); Inactivated porcine circovirus type 2 (PCV2) vaccines, won the First Class State Science & Technology Progress Award in 2012.

 

Miles Yao

CEO
BioVantage

Miles Yao had studied virology and he holds a Master Degree in Preventive Veterinary Medicine from China Agriculture University, he also holds Master Degrees in Agricultural Economics from Purdue University, and an MBA from Indiana University-Kelley School of Business. Prior to this, he studied in Huazhong Agricultural University and earned an Animal Science Degree.

Miles Yao

CEO
BioVantage

Miles Yao had studied virology and he holds a Master Degree in Preventive Veterinary Medicine from China Agriculture University, he also holds Master Degrees in Agricultural Economics from Purdue University, and an MBA from Indiana University-Kelley School of Business. Prior to this, he studied in Huazhong Agricultural University and earned an Animal Science Degree.

 Miles Yao founded MarketVisor AgConsulting in 2015, and since then serves as its Managing Director, responsible for market development and entry strategies, as well as day-to-day engagement with commercial, government, and trade association contacts for clients. He and his team at MarketVisor are business partners for some leading trade associations and international and domestic animal health companies.

In 2018, Miles founded BioVantage with other investing partners, committing to be a Contract Research Organization in animal health sector. 

 

Prior to being an entrepreneur, Miles has worked in leadership roles overseeing commercial and regulatory affairs with a Hong Kong based agribusiness company. He has lead China market entry strategies for agricultural products and animal health products from clients in the US, Mexico and EU. In these roles, Miles has ensured the market access, developed and managed distribution networks, key in-market client relationships and day-to day business activity. 

From 2007-2013, Miles also worked in the Beijing USDA-APHIS office promoting safe and sustainable agriculture trade in China, Hong Kong, Macau and Mongolia. His primary focuses were technical and trade consultations between Government and industry, trade barrier reduction and negotiation, and agriculture policy analysis and execution. Miles had worked with Boehringer Ingelheim Animal Health for two years during 2005-2007, while at BI, his primary focus was swine sector. He also worked in poultry sector with Beijing Efficacy Biotech Co. as a Technical Manager for some time.

 

Contact:

[email protected]

 

Randolph Seidler

VP, Global Head of Business Development Animal
Boehringer Ingelheim

Randolph Seidler

VP, Global Head of Business Development Animal
Boehringer Ingelheim
 

Mark J. Micallef

Division Director International Business
Zenoaq

Mark J. Micallef

Division Director International Business
Zenoaq
 

Rob Kelly

President International Operations
Zoetis Inc.

Rob Kelly

President International Operations
Zoetis Inc.
 

Nicolas Besse

External Development Director
Adisseo

Nicolas Besse

External Development Director
Adisseo
 

Kyoon Andrew Kim

SVP Head of Marketing & Finance
Plumbline Life Sciences Inc.
• Standard Chartered Bank, Korea Investment Holdings Co. Ltd.
• Franklin Templeton Investment, Macquarie-IMM Investment
• Abbott Lab, Bristol Myers & Squibb
• Baldwin-Wallace University, MBA
• Ph.D. ABD. / Business Administration, Sejong University

Kyoon Andrew Kim

SVP Head of Marketing & Finance
Plumbline Life Sciences Inc.
• Standard Chartered Bank, Korea Investment Holdings Co. Ltd.
• Franklin Templeton Investment, Macquarie-IMM Investment
• Abbott Lab, Bristol Myers & Squibb
• Baldwin-Wallace University, MBA
• Ph.D. ABD. / Business Administration, Sejong University
 

Norman Lee

President
Tianjin Ringpu Bio-Technology Co. Ltd.

Norman Lee, Ph.D., Professor and founder of Tianjin Ringpu Bio-Technology Co. Ltd., Director of the MOA’s Key Laboratory for Veterinary Drug Innovation, Chairman of the National Veterinary Drug Industry Strategic Alliance for Technology and Innovation, Vice-President of the Chinese Veterinary Association, President of the Tianjin Veterinary Medicine Association, post-graduate advisor at the Tianjin Agricultural University. Dr. Lee has led over 21 national, provincial, and municipal science and technology projects.

Norman Lee

President
Tianjin Ringpu Bio-Technology Co. Ltd.

Norman Lee, Ph.D., Professor and founder of Tianjin Ringpu Bio-Technology Co. Ltd., Director of the MOA’s Key Laboratory for Veterinary Drug Innovation, Chairman of the National Veterinary Drug Industry Strategic Alliance for Technology and Innovation, Vice-President of the Chinese Veterinary Association, President of the Tianjin Veterinary Medicine Association, post-graduate advisor at the Tianjin Agricultural University. Dr. Lee has led over 21 national, provincial, and municipal science and technology projects. He was recipient of the second prize of the National Science and Technology Progress Award and twice of the first prize of the Tianjin Science and Technology Progress Award.

In 1998, Dr. Lee established Ringpu(Tianjin)Bio-Pharmacy Co. Ltd. And Ringpu (Baoding) Biological Pharmaceutical Co., Ltd. He also acted as General Manager of both companies.

In 2004, he was in charge of the research project: “Genetically engineering recombinant chicken α- interferon”. The project received the first prize of the Tianjin City Technology Innovation Award.

In 2008, he led a management team to restructure the company and established Tianjin Ringpu Bio-Technology Co. Ltd. He was appointed Acting Chairman of the Board.

On 17th September 2010, Tianjin Ringpu Bio-Technology Co. Ltd. was officially listed on the Shenzhen Stock Exchange and Dr. Lee is Chairman of the Board,

In 2012, Dr. Lee was part of the research team: “Swine and poultry pathogenic bacteria resistance research and its application in development of a safe and effective new veterinary drug”. The project received the second prize of the National Science and Technology Progress Award.

 

Kristin Bloink

Senior Director of Global Research and External Innovation
Elanco

Kristin Bloink manages all internal discovery efforts and all external technology evaluations and subsequent portfolio entries for R&D.   She has 26 years of accomplishments in human clinical trials, animal drug discovery and development, translational model development and execution, and human and veterinary clinical medical delivery in the private as well as the military sector.  She joined Novartis Animal Health in 2007 and integrated into Elanco Animal Health in 2015.   

Kristin Bloink

Senior Director of Global Research and External Innovation
Elanco

Kristin Bloink manages all internal discovery efforts and all external technology evaluations and subsequent portfolio entries for R&D.   She has 26 years of accomplishments in human clinical trials, animal drug discovery and development, translational model development and execution, and human and veterinary clinical medical delivery in the private as well as the military sector.  She joined Novartis Animal Health in 2007 and integrated into Elanco Animal Health in 2015.   

 

Klaus Hellmann

Managing Director
Klifovet

Klaus Hellmann

Managing Director
Klifovet
 

Mark Engel

CEO
Phagelux

Mark Engel

CEO
Phagelux
 

Carel du Marchie Sarvaas

Executive Director
HealthforAnimals

Carel du Marchie Sarvaas has been working as a senior government affairs and communications advisor in Brussels and Washington DC for 20 years.

He will move to IFAH from EuropaBio, the Association of Biotechnology Industries, where he has been Director for Agricultural Biotechnology for some 4 years. Prior to EuropaBio, Carel worked at international consultancies and think tanks in Brussels and Washington DC, most often serving clients with science-based policy and communications challenges.

Carel du Marchie Sarvaas

Executive Director
HealthforAnimals

Carel du Marchie Sarvaas has been working as a senior government affairs and communications advisor in Brussels and Washington DC for 20 years.

He will move to IFAH from EuropaBio, the Association of Biotechnology Industries, where he has been Director for Agricultural Biotechnology for some 4 years. Prior to EuropaBio, Carel worked at international consultancies and think tanks in Brussels and Washington DC, most often serving clients with science-based policy and communications challenges.

Carel is experienced in the interplay between regulatory, political and communications issues as they relate to science, innovation and policy. A Dutch national, he is married and has four children. He has lived in South Africa, Canada, Brussels, and Paris and holds degrees from the University of Leiden and Johns Hopkins Universi

 

Yuki Ujimasa

President
AHRMS, Inc

Yuki Ujimasa

President
AHRMS, Inc
 

Prof. Seong Kyu Song

Handong University

Prof. Seong Kyu Song

Handong University
 

Dr. Johnny A. Jacobsen

Global Head of Business Development
Argenta

Johnny was appointed to a new role with Argenta in early 2017 as Global Head of Customer Experience and subsequently promoted in 2018 to be the Global Head of Business Development.  In this new role, Johnny is leading a team focused on client engagement and relationship management and he also is responsible for the development and execution of the strategic direction of Argenta’s global marketing, branding and communications.

Dr. Johnny A. Jacobsen

Global Head of Business Development
Argenta

Johnny was appointed to a new role with Argenta in early 2017 as Global Head of Customer Experience and subsequently promoted in 2018 to be the Global Head of Business Development.  In this new role, Johnny is leading a team focused on client engagement and relationship management and he also is responsible for the development and execution of the strategic direction of Argenta’s global marketing, branding and communications.

Headline Partner

Become a Sponsor

Kisaco Research provides the much needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.

Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.

With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.

Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].

Register

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

Monday, October 1, 2018 to Friday, November 1, 2019
Emerging & Academic Pass
$799 USD
Super Early Bird rate
Contact [email protected] for discounted emerging pass rates
Pre-revenue companies
Academics
AH Biotech Companies up to $10 Million in annual revenue
Charities
Please note: Those offering consultancy or market intelligence services do not qualify for this rate
Monday, October 1, 2018 to Friday, November 1, 2019
Delegate Pass
$1,699 USD
Super Early Bird rate
Pharmaceutical Manufacturers
Digital & Tech Companies
Biotech Companies over $10m in annual revenue
Monday, October 1, 2018 to Friday, November 1, 2019
Multinational Pass
$1,999 USD
Super Early Bird rate
Companies over $100m annual revenue
Monday, October 1, 2018 to Friday, November 1, 2019
Service Provider Pass
$1,999 USD
Super Early Bird rate
CROs & CMOs
Consultants, M&A Advisors
Private Equity Investors & Brokers
Start-Up Incubators & Accelerators
Distribution Companies
Preparing registration...

Venue

Tokyo, Japan

Venue and Accommodation details coming soon

Global Advisory Board

WHO THEY ARE

Each of our Advisory Board members have been chosen based on numerous recommendations, their deep knowledge and Industry experience and ability to provide a clear vision, not just for their own organizations, but for the industry as a whole.

WHY THEY ARE HERE

Board members guide not just content, but also the underlying mission of the events to drive positive change.

Aaron Schacht

Vice President - Global Research and Development
Elanco

Jishu Shi

Director, U.S.-China Center for Animal Health
Kansas State University

Alan Mackay

Executive Partner and Founder
GHO Capital

George Gunn

Founder and CEO
Stonehaven Consulting AG

Linda Rhodes

VMD, PhD

Joachim Hasenmaier

Member of the Board of Managing Directors
BOEHRINGER INGELHEIM

Clinton Lewis

Clinton Lewis Executive Vice President, President, International Operations
ZOETIS

Dirk Ehle

Head of Bayer Animal Health
Bayer

Dr. James Lloyd

Dean of the College and Professor
University of Florida, Colleague of Veterinary Medicine

Sébastien Huron

Chairman of the Executive Board
Virbac Santé Animale

2018 Selection Committee

Tony Zi Long Tan

Founder and Managing Partner
Z-LINK BIOTECH

Dr. Hu Hongbin

President
EFEV Group

Miles Yao

CEO
BioVantage

Mark Heffernan

CEO
Stonehaven Incubate

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us

We need some information to know how best to respond to your request below.

To prevent automated spam submissions leave this field empty.

Subject Access Requests: If you would like a copy of the data/information we hold about you, please email [email protected].

User Deletion Request: If you wish to have your information that is held by Kisaco Research deleted, please email [email protected].

For more information on Kisaco Research policy and procedures, please visit our Privacy Policy.